Sebelipase Alfa (Kanuma)

Sebelipase alfa is a recombinant enzyme-replacement drug for lysosomal acid lipase (LAL) deficiency, a rare inherited disorder in which a missing enzyme lets fat build up in the liver, spleen and blood vessels. One gene defect produces two very different diseases depending on how much enzyme activity is left: a rapidly fatal infantile form historically called Wolman disease, and a slower, later-onset form (cholesteryl ester storage disease) that can go undiagnosed for decades. Approved in 2015 as the first disease-specific treatment for either, it's also manufactured in a way no other drug on this site is — purified from the egg whites of a line of genetically engineered chickens, only the second FDA-approved drug ever produced by a genetically modified animal.

Two diseases, one missing enzyme

Lysosomal acid lipase (LAL) deficiency is a rare, autosomal recessive disorder caused by mutations in the LIPA gene, which encodes an enzyme that normally breaks down cholesteryl esters and triglycerides delivered into cells by LDL particles. Without enough working LAL, those fats accumulate inside lysosomes throughout the body, especially in the liver, spleen, gut and blood vessel walls. The same underlying gene defect produces two clinically distinct diseases depending on how much residual enzyme activity a patient's specific mutations leave. The most severe form, historically called Wolman disease, involves essentially total loss of LAL activity and presents in infancy with severe hepatosplenomegaly, malabsorption and adrenal calcification; without treatment it is fatal, historically with a median survival of well under a year. The milder, partial-activity form, cholesteryl ester storage disease (CESD), can present anywhere from childhood to adulthood with liver disease, abnormal cholesterol levels and early atherosclerosis, and can go undiagnosed for decades. Before sebelipase alfa, neither form had a disease-specific treatment: infants died of liver failure and malnutrition, while CESD patients were managed with statins and, in severe cases, liver transplant — neither of which addressed the missing enzyme itself.

Sebelipase alfa is a recombinant form of human LAL, developed by Synageva BioPharma and carried through approval by Alexion Pharmaceuticals after Alexion's 2015 acquisition of Synageva. Because both presentations of LAL deficiency share the identical underlying molecular cause even though their clinical course differs enormously, Alexion sought and received a single FDA approval covering the full disease spectrum — rapidly progressive infantile disease and later-onset disease alike — built on two genuinely different kinds of clinical evidence, described in the next two sections.

Infants: judged against history, because there was no time for a placebo trial

This is a genuinely different evidentiary standard from a randomized trial, and it's worth being explicit about the trade-off: a historical-control comparison is more vulnerable to confounding — different eras of supportive care, different diagnostic criteria — than a concurrent randomized trial would be. But the size of the survival difference — a disease with essentially no long-term survivors in the untreated historical group, against roughly half of treated infants alive past four years — was large enough that the FDA accepted it as sufficient evidence of effect in a population where withholding treatment to run a cleaner trial design was not considered defensible.

Older children and adults: the placebo-controlled ARISE trial

For the later-onset population, a randomized, double-blind, placebo-controlled design was both ethical and feasible, since the slower course of cholesteryl ester storage disease gave a placebo-treated comparison group time to be safely studied. The pivotal ARISE trial randomized 66 patients aged 4 and older with LAL deficiency (the large majority with the later-onset phenotype) to sebelipase alfa (1 mg/kg every other week) or placebo for a 20-week double-blind phase, followed by open-label treatment for everyone. The primary endpoint — normalization of alanine aminotransferase (ALT), a standard liver-injury marker — was met by 31% of the sebelipase alfa group versus 7% on placebo (P=0.03), with significant improvements also seen in LDL cholesterol, triglycerides and liver fat content (Burton BK, Balwani M, Feillet F, et al., “A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency,” N Engl J Med 2015;373(11):1010-1020, PMID 26352813, DOI: 10.1056/NEJMoa1501365).²

The FDA approved Kanuma for the full range of LAL deficiency — infantile-onset and later-onset presentations alike, across ages — on 8 December 2015. The European Medicines Agency had granted marketing authorization several months earlier, in August 2015, making the EU approval sebelipase alfa's first anywhere in the world.

The second FDA-approved drug made in a genetically engineered animal

Alexion itself changed hands during this period: AstraZeneca completed its roughly $39-41 billion acquisition of Alexion Pharmaceuticals on 21 July 2021, and Kanuma is now marketed under Alexion AstraZeneca Rare Disease. That deal followed Alexion's own 2015 acquisition of Synageva BioPharma, sebelipase alfa's original developer, for approximately $8.4 billion, announced 6 May 2015 and completed 22 June 2015.

Current status

Kanuma remains FDA-approved and currently marketed by Alexion AstraZeneca Rare Disease as the only disease-specific treatment for LAL deficiency in either the infantile or later-onset form. Published health-technology assessments have put its annual cost anywhere from roughly $890,000 to nearly $5 million per patient depending on body weight and disease presentation — among the higher end of the enzyme-replacement drug pricing this site covers, reflecting both the manufacturing complexity described above and the extremely small number of diagnosed patients worldwide.